Cargando…

Nivolumab‐induced fulminant type 1 diabetes with precipitous fall in C‐peptide level

We describe here a case of nivolumab‐induced type 1 diabetes, which developed within 9 days of treatment. The case highlights the importance of frequent monitoring of glucose after initiation of nivolumab treatment.[Image: see text]

Detalles Bibliográficos
Autores principales:	Miyauchi, Masaaki, Toyoda, Masao, Zhang, Jie, Hamada, Naoko, Yamawaki, Takashi, Tanaka, Jun, Harada, Kazuki, Kashizaki, Fumihiro, Fukagawa, Masafumi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7232357/ https://www.ncbi.nlm.nih.gov/pubmed/31587459 http://dx.doi.org/10.1111/jdi.13143

Ejemplares similares

Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor
por: Miyauchi, Masaaki, et al.
Publicado: (2017)

Exercise Therapy for Management of Type 2 Diabetes Mellitus: Superior Efficacy of Activity Monitors over Pedometers
por: Miyauchi, Masaaki, et al.
Publicado: (2016)

A Patient with Nivolumab-related Fulminant Type 1 Diabetes Mellitus whose Serum C-peptide Level Was Preserved at the Initial Detection of Hyperglycemia
por: Yamamoto, Naoko, et al.
Publicado: (2019)

Nivolumab-induced fulminant diabetic ketoacidosis followed by thyroiditis
por: Tzoulis, Ploutarchos, et al.
Publicado: (2018)

Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab
por: Chokr, Nora, et al.
Publicado: (2018)

Upregulation of α3β1-Integrin in Podocytes in Early-Stage Diabetic Nephropathy
por: Sawada, Kaichiro, et al.
Publicado: (2016)

Efficacy of lorlatinib after alectinib-induced interstitial lung disease in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer: a case report
por: Kashizaki, Fumihiro, et al.
Publicado: (2022)

An Autopsy Case of Late-onset Fulminant Myocarditis Induced by Nivolumab in Gastric Cancer
por: Naganuma, Ken, et al.
Publicado: (2022)

Behavior Modification Maintenance with Long-Term Blood Glucose and Weight Management in Prader–Willi Syndrome Complicated with Diabetes: Team Management Approach Combined with Pharmacological Treatment
por: Kato, Eri, et al.
Publicado: (2019)

Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy
por: Nishimura, Tomoka, et al.
Publicado: (2022)

Successful use of equine anti-thymocyte globulin (ATGAM) for fulminant myocarditis secondary to nivolumab therapy
por: Tay, Rebecca Y, et al.
Publicado: (2017)

Fulminant myocarditis induced by immune checkpoint inhibitor nivolumab: a case report and review of the literature
por: Wang, Feifei, et al.
Publicado: (2021)

Precipitating Mechanisms of Falls in Preclinical Alzheimer’s Disease
por: Keleman, Audrey A., et al.
Publicado: (2023)

Diversity in fall characteristics hampers effective prevention: the precipitants, the environment, the fall and the injury
por: Sanders, K. M., et al.
Publicado: (2017)

SUN-173 Nivolumab-Induced Fulminant Autoimmune Diabetes Presenting as Diabetic Ketoacidosis in a Patient with Melanoma
por: Parikh, Sahil, et al.
Publicado: (2019)

A Liquid-Based Cytology System, without the Use of Cytocentrifugation, for Detection of Podocytes in Urine Samples of Patients with Diabetic Nephropathy
por: Kimura, Moritsugu, et al.
Publicado: (2019)

Corrigendum to “A Liquid-Based Cytology System, without the Use of Cytocentrifugation, for Detection of Podocytes in Urine Samples of Patients with Diabetic Nephropathy”
por: Kimura, Moritsugu, et al.
Publicado: (2020)

Deep hyperammonemic hepatic encephalopathy precipitated by fecal microbiota transplantation for fulminant Clostridioides difficile infection
por: Eriksen, Lotte Lindgreen, et al.
Publicado: (2021)

Long-term complete response in small cell bladder carcinoma treated with carboplatin, etoposide, and atezolizumab
por: Kamitani, Rei, et al.
Publicado: (2022)

Fulminant Hepatic Failure after Chemosaturation with Percutaneous Hepatic Perfusion and Nivolumab in a Patient with Metastatic Uveal Melanoma
por: Teal, Lindsey, et al.
Publicado: (2021)

Clinical Phenotypes and the Clinical Course of Bullous Pemphigoid Receiving Dipeptidyl Pepitidase-4 Inhibitor Treatment: An Analysis of Cases in a Single Japanese Center
por: Nakagawa, Yosuke, et al.
Publicado: (2022)

Living Donor Liver Transplantation for Wilson’s Disease Associated with Fulminant Hepatic Failure: A Case Report
por: Huang, Yu, et al.
Publicado: (2018)

Vascular-type Ehlers-Danlos syndrome caused by a hitherto unknown genetic mutation: a case report
por: Kashizaki, Fumihiro, et al.
Publicado: (2013)

Severe Gastritis after Administration of Nivolumab and Ipilimumab
por: Nishimura, Yoshito, et al.
Publicado: (2018)

The Importance of Patient and Family Engagement, the Needs for Self-Monitoring of Blood Glucose (SMBG) – Our Perspectives Learned Through a Story of SMBG Assistive Devices Made by a Husband of the Patient with Diabetes
por: Kimura, Moritsugu, et al.
Publicado: (2022)

Regulation of Renin Expression by Β1-Integrin in As4.1 Juxtaglomerular Line Cells
por: Saito, Nobumichi, et al.
Publicado: (2023)

A Survey on the Current Status of Ophthalmological Consultations in Patients With Diabetes Undergoing Maintenance Hemodialysis and the Effectiveness of Education on Consultation Behavior –Experience of a Single Hemodialysis Clinic in Japan
por: Kimura, Moritsugu, et al.
Publicado: (2022)

Transition of the PD-1 occupancy of nivolumab on T cells after discontinuation and response of nivolumab re-challenge
por: Nose, Taku, et al.
Publicado: (2022)

Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy
por: Lowe, Jared R., et al.
Publicado: (2016)

Precipitous Fall in Common Respiratory Viral Infections During COVID-19
por: Parry, Michael F, et al.
Publicado: (2020)

Fulminant Amebic Enteritis in the Perinatal Period
por: Azuma, Daisuke, et al.
Publicado: (2022)

Relapsed Myasthenia Gravis after Nivolumab Treatment
por: Mitsune, Ayumi, et al.
Publicado: (2018)

Medical management after parathyroid intervention
por: Tanaka, Motoko, et al.
Publicado: (2008)

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
por: Lee, Alexandria T M, et al.
Publicado: (2023)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

Nivolumab treatment followed by atezolizumab induced encephalitis and neuropathy with antiganglioside antibodies
por: Watanabe, Shohei, et al.
Publicado: (2021)

Case of fulminant type 1 diabetes with coronary microcirculatory dysfunction
por: Yamada, Hodaka, et al.
Publicado: (2014)

Fulminating Appendicitis
Publicado: (1901)

Fulminant meningococcemia
por: Fidrocki, Diana, et al.
Publicado: (2017)

Fulminant hepatitis
por: Sinclair, Stephen, et al.
Publicado: (1990)

Cannot write session to /tmp/vufind_sessions/sess_p3pn849lhimfoitlefo035d3p1